Roche’s TIGIT flop prompts GSK, iTeos to reevaluate next steps for rival drug – FierceBiotech

  1. Roche’s TIGIT flop prompts GSK, iTeos to reevaluate next steps for rival drugFierceBiotech
  2. Study Results Show Genentech’s Tiragolumab Did Not Meet Primary EndpointsPharmacy Times
  3. New class of cancer drugs down, not out, after Roche trial setback – analystsReuters
  4. Roche believes cancer drug setback is not a fatal blow to growth prospectsReuters
  5. View Full Coverage on Google News

.

Leave a Comment

Your email address will not be published.